Compare Medpace Holdings Inc (MEDP) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Procter & Gamble Co — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.87B), while Procter & Gamble Co trades at $150 (market cap $343.34B). The key difference: Procter & Gamble Co is far larger — about 20.4× Medpace Holdings Inc's market cap, and Procter & Gamble Co pays a 2.95% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Procter & Gamble Co for 131 Days on average.
| MEDP | PG | |
|---|---|---|
Market Cap | $16.87B | $343.34B |
Volume | 207,570 | 8,662,344 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $167.18 |
52-Week Low | $393.42 | $138.10 |
Typical Hold Time | 14 Days | 131 Days |
Enterprise Value | $16.48B | $369.18B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Procter & Gamble (PG) trades at $150.59, up 1.47% today, with a bullish technical signal from moving averages and a consensus analyst price target of $160.13. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and strong profitability margins. Recent earnings have consistently beaten expectations, and the stock offers a dividend yield with a history of increases.
PG presents a stable investment with consistent earnings and dividend growth, supported by a robust balance sheet. Risks include premium valuation multiples and modest revenue growth outlook. Analyst sentiment is predominantly positive, with 53% buy ratings, but investors should monitor competitive pressures and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
